See more : Western Energy Services Corp. (WRG.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Trevena, Inc. (TRVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trevena, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Signature Bank (SBNYP) Income Statement Analysis – Financial Results
- Stantec Inc. (STN) Income Statement Analysis – Financial Results
- Meten EdtechX Education Group Ltd. (METXW) Income Statement Analysis – Financial Results
- HBI-Hyperion SE (A7K.DU) Income Statement Analysis – Financial Results
- CryptoStar Corp. (CSTR.V) Income Statement Analysis – Financial Results
Trevena, Inc. (TRVN)
About Trevena, Inc.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.13M | -418.00K | 567.00K | 3.07M | 31.00K | 5.73M | 0.00 | 3.75M | 6.25M | 0.00 | 134.98K | 807.60K | 2.42M |
| Cost of Revenue | 1.67M | 3.02M | 954.00K | 182.00K | 108.00K | 0.00 | 490.00K | 0.00 | 44.07M | 40.55M | 18.76M | 13.29M | 0.00 |
| Gross Profit | 1.46M | -3.44M | -387.00K | 2.89M | -77.00K | 5.73M | -490.00K | 3.75M | -37.82M | -40.55M | -18.63M | -12.49M | 2.42M |
| Gross Profit Ratio | 46.56% | 822.01% | -68.25% | 94.07% | -248.39% | 100.00% | 0.00% | 100.00% | -605.18% | 0.00% | -13,800.00% | -1,546.24% | 100.00% |
| Research & Development | 16.33M | 18.21M | 13.43M | 13.12M | 13.29M | 15.82M | 48.97M | 89.96M | 44.07M | 40.55M | 18.76M | 13.29M | 15.11M |
| General & Administrative | 0.00 | 0.00 | 38.11M | 19.25M | 13.21M | 18.98M | 19.64M | 16.08M | 12.80M | 9.40M | 4.72M | 3.12M | 3.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.41M | 34.73M | 38.11M | 19.25M | 13.21M | 18.98M | 19.64M | 16.08M | 12.80M | 9.40M | 4.72M | 3.12M | 3.06M |
| Other Expenses | 0.00 | 2.71M | 337.00K | 416.00K | 2.25M | 459.00K | 614.00K | -711.00K | 92.93K | 184.02K | 1.25K | 122.79K | 0.00 |
| Operating Expenses | 38.41M | 52.94M | 51.54M | 32.37M | 26.50M | 34.80M | 68.61M | 106.03M | 56.87M | 49.95M | 23.48M | 16.42M | 18.17M |
| Cost & Expenses | 38.41M | 55.96M | 52.49M | 32.55M | 26.50M | 34.80M | 68.61M | 106.03M | 56.87M | 49.95M | 23.48M | 16.42M | 18.17M |
| Interest Income | 2.25M | 451.00K | 162.00K | 240.00K | 418.00K | 1.00M | 679.00K | 743.00K | 331.21K | 17.37K | 884.00 | 754.00 | 3.54K |
| Interest Expense | 0.00 | 1.26M | 1.00K | 29.00K | 931.00K | 2.23M | 2.78M | 1.74M | 334.37K | 70.65K | 149.76K | 193.74K | 74.22K |
| Depreciation & Amortization | 893.00K | 864.00K | 841.00K | 830.00K | 863.00K | 645.00K | 490.00K | 246.00K | 207.90K | 239.39K | 706.78K | 787.52K | 801.58K |
| EBITDA | -35.29M | -55.51M | -51.08M | -28.66M | -25.61M | -28.43M | -68.12M | -101.01M | -50.62M | -49.71M | -22.64M | -14.65M | -14.95M |
| EBITDA Ratio | -1,129.22% | 13,486.84% | -9,157.85% | -960.74% | -74,961.29% | -482.27% | 0.00% | -2,727.55% | -809.94% | 0.00% | -16,770.17% | -1,820.09% | -617.21% |
| Operating Income | -35.29M | -56.38M | -51.93M | -29.49M | -26.58M | -30.50M | -70.39M | -102.28M | -50.62M | -49.95M | -23.35M | -15.61M | -15.75M |
| Operating Income Ratio | -1,129.22% | 13,486.84% | -9,157.85% | -960.74% | -85,741.94% | -532.07% | 0.00% | -2,727.55% | -809.94% | 0.00% | -17,295.37% | -1,932.90% | -650.46% |
| Total Other Income/Expenses | -4.68M | 2.71M | 337.00K | 416.00K | 1.71M | 459.00K | -3.25M | -711.00K | 92.76K | 249.13K | 93.85K | -25.62K | -59.79K |
| Income Before Tax | -39.97M | -53.67M | -51.59M | -29.07M | -24.87M | -30.04M | -71.87M | -102.99M | -50.53M | -49.70M | -23.25M | -15.64M | -15.81M |
| Income Before Tax Ratio | -1,279.07% | 12,839.71% | -9,098.41% | -947.18% | -80,229.03% | -524.06% | 0.00% | -2,746.51% | -808.45% | 0.00% | -17,225.84% | -1,936.08% | -652.93% |
| Income Tax Expense | 318.00K | -2.71K | -428.00K | 300.00K | 3.19M | 745.00K | 3.39M | -246.00K | -207.90K | 254.67K | 151.00K | 316.53K | 74.22K |
| Net Income | -40.29M | -53.67M | -51.16M | -29.37M | -28.06M | -30.78M | -71.87M | -102.99M | -50.53M | -49.70M | -23.25M | -15.64M | -15.81M |
| Net Income Ratio | -1,289.25% | 12,839.07% | -9,022.93% | -956.96% | -90,503.23% | -537.06% | 0.00% | -2,746.51% | -808.45% | 0.00% | -17,225.84% | -1,936.08% | -652.93% |
| EPS | -54.51 | -14.88 | -7.82 | -4.86 | -7.65 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 | -22.59 | -28.41 | -38.03 |
| EPS Diluted | -54.51 | -14.88 | -7.77 | -4.86 | -7.65 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 | -22.59 | -28.41 | -38.03 |
| Weighted Avg Shares Out | 739.05K | 3.61M | 6.54M | 6.05M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.22K | 1.03M | 550.43K | 415.72K |
| Weighted Avg Shares Out (Dil) | 739.05K | 3.61M | 6.58M | 6.05M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.22K | 1.03M | 550.43K | 415.72K |
Trevena, Inc. Announces Registered Direct Offering of Preferred Stock
CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it...
Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update
OLINVYK demonstrated statistically significant reduced impact on neurocognitive functioning vs IV morphine on primary endpoint
Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care
CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication in Expert Review of...
Best Penny Stocks to Buy Next Week? 3 to Watch?
Can these penny stocks make gains this coming week? The post Best Penny Stocks to Buy Next Week?
Trevena to Participate at the JMP Securities Life Sciences Conference
CHESTERBROOK, Pa., June 10, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO,...
Trevena to Present at the H.C. Wainwright Global Investment Conference
CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO...
Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q1 2022 Results - Earnings Call Transcript
Trevena, Inc. (NASDAQ:TRVN ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Barry Shin - Senior Vice President & Chief Financial Officer Carrie Bourdow - President & Chief Executive Officer Patty Drake - Chief Commercial...
Trevena (TRVN) Reports Q1 Loss, Lags Revenue Estimates
Trevena (TRVN) delivered earnings and revenue surprises of -11.11% and 96.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Trevena Reports First Quarter 2022 Results and Provides Business Update
OLINVYK refocused commercial strategy initiated mid-Q1
Trevena to Release First Quarter 2022 Financial Results on May 11, 2022
Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET
Source: https://incomestatements.info
Category: Stock Reports